Drug Patents owned by Lupin

1. Drug name - ANTARA (MICRONIZED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8026281 LUPIN Treating metabolic syndrome with fenofibrate Apr, 2025

(2 years from now)

US9314447 LUPIN Reduced dose pharmaceutical compositions of fenofibrate May, 2033

(10 years from now)

Drugs and Companies using FENOFIBRATE ingredient

Treatment: Treating severe hypertriglyceridemia; treating primary hypercholesterolemia and mixed dyslipidemia; Treating primary hypercholesterolemia and mixed dyslipidemia; treating severe hypertriglyceridemia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG CAPSULE;ORAL Prescription
43MG CAPSULE;ORAL Prescription
87MG CAPSULE;ORAL Discontinued
90MG CAPSULE;ORAL Prescription
130MG CAPSULE;ORAL Prescription

2. Drug name - SESQUIENT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750822 LUPIN Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US7635773 LUPIN Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US8410077 LUPIN Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US9200088 LUPIN Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US9493582 LUPIN Alkylated cyclodextrin compositions and processes for preparing and using the same Feb, 2033

(10 years from now)

Drugs and Companies using FOSPHENYTOIN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML) SOLUTION;INTRAVENOUS Discontinued
EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML) SOLUTION;INTRAVENOUS Discontinued

3. Drug name - SOLOSEC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335390 LUPIN Secnidazole for use in the treatment of bacterial vaginosis Sep, 2035

(12 years from now)

US11000507 LUPIN Secnidazole for use in the treatment of bacterial vaginosis Sep, 2035

(12 years from now)

US11020377 LUPIN Secnidazole for use in the treatment of bacterial vaginosis Sep, 2035

(12 years from now)

US11000508 LUPIN Secnidazole for use in the treatment of trichomoniasis Sep, 2035

(12 years from now)

US10849884 LUPIN Secnidazole for use in the treatment of bacterial vaginosis Sep, 2035

(12 years from now)

US10682338 LUPIN Secnidazole for use in the treatment of bacterial vaginosis Sep, 2035

(12 years from now)

US10857133 LUPIN Secnidazole for use in the treatment of bacterial vaginosis Sep, 2035

(12 years from now)

Drugs and Companies using SECNIDAZOLE ingredient

Treatment: Treatment of bacterial vaginosis in adult women; treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of trichomoniasis in patients 12 years of age and older; treatment of bacterial vaginosis in female patients 12 years of age and older; treatment of trichomoniasis in adults; treatment of bacterial vaginosis in adult women; Treatment of bacterial vaginosis in female patients 12 years of age and older; treatment of trichomoniasis in patients 12 years of age and older; treatment of trichomoniasis in adults; treatment of bacterial vaginosis in adult women; Treatment of bacterial vaginosis in female patients 12 years of age and older; treatment of bacterial vaginosis in adult women

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
2GM/PACKET GRANULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.